Intervenção coronária percutânea em pontes de veia safena com uso de stents farmacológicos: resultados agudos e tardios dos pacientes incluídos no registro DESIRE / Percutaneous coronary intervention en saphenous vein bypass grafts with drug-eluting stents: early and late outcomes of patients in the DESIRE registry

RESUMO

Mesmo com o advento dos stents farmacológicos, a intervenção coronária percutânea em pontes de veia safena permanece desafiadora, com elevada incidência de complicações agudas e incerteza dos resultados clínicos de pacientes com lesões em pontes de veia safena tratados com stents farmacológicos. Método: Entre maio de 2002 e janeiro de 2009, 151 pacientes com 196 lesões em pontes de veia safena foram consecutivamente submetidos a intervenção coronária percutânea com 211 stents farmacológicos e incluídos neste estudo. Os pacientes foram pré-tratados com enoxaparina, clopidogrel e ácido acetilsalicílico por 3 a 5 dias antes da intervenção coronária percutânea. A terapia antiplaquetária dupla (ácido acetilsalicílico + clopidogrel) foi prescrita por 12 meses. Objetivou-se determinar as taxas de eventos cardíacos adversos maiores (ECAM) no período hospitalar e na fase tardia. Seguimento clínicofoi obtido com 1, 6 e 12 meses e, então, anualmente...

ABSTRACT

Introduction: Despite the advent of drug-eluting stents, percutaneous coronary interventions in saphenous vein bypass grafts remain a challenge, with a high incidence of early complications and uncertainty regarding late outcomes. This study was aimed at evaluating clinical outcomes of patients with saphenous vein graft lesions treated with drug-eluting stents. Method: From May 2002 to January 2009, a total of 151 patients with 196 saphenous vein graft lesions were consecutively submitted to percutaneous coronary intervention with 211 drug-eluting stents and included in this trial. Patients were pretreated with enoxiparin, clopidogrel and acetylsalicylic acid for 3 to 5 days prior to percutaneous coronary intervention. Dual antiplatelet therapy (acetylsalicylic acid + clopidogrel) was prescribed for 12 months. The objective was to determine the rate of major adverse cardiac events (MACE) during hospitalization and in the long-term. Clinical follow-up was obtained at 1, 6 and 12 months and then, yearly after that...